190 results on '"Rahn KH"'
Search Results
2. Alterations of plasma calcium and intracellular and membrane calcium in erythrocytes of patients with pre-eclampsia
- Author
-
Kosch, M, Hausberg, M, Louwen, F, Barenbrock, M, Rahn, KH, and Kisters, K
- Published
- 2000
- Full Text
- View/download PDF
3. Studies on diurnal blood pressure variation in kidney diseases associated with excessive salt and water retention
- Author
-
Barenbrock, M, Spieker, C, Hausberg, M, Rahn, KH, Zidek, W, and Kisters, K
- Published
- 1999
- Full Text
- View/download PDF
4. A longitudinal study of vessel wall properties in normotensive and hypertensive renal transplant recipients
- Author
-
Barenbrock, M, Hausberg, M, Kosch, M, Kisters, K, Hoeks, APG, and Rahn, KH
- Published
- 1998
- Full Text
- View/download PDF
5. Decreased cellular Mg2+ concentrations in a subgroup of hypertensives – cell models for the pathogenesis of primary hypertension
- Author
-
Kisters, K, Tepel, M, Spieker, C, Dietl, KH, Barenbrock, M, Rahn, KH, and Zidek, W
- Published
- 1997
- Full Text
- View/download PDF
6. Renal function in treated and untreated hypertension
- Author
-
Rahn, KH
- Published
- 1998
- Full Text
- View/download PDF
7. AMELIORATION OF ARTERIAL PROPERTIES WITH A PERINDOPRIL-INDAPAMIDE
- Author
-
ASMAR RG, LONDON GM, O'ROURKE ME, MALLION JM, ROMERO R, RAHN KH, TRIMARCO, BRUNO, FITZGERALD D, HEDNER T, DUPREZ D, DE LEEUW PW, SEVER P, BATTEGAY E, HITZENBERGER G, DE LUCA, NICOLA, POLONIA P, BENETOS A, CHASTANG C, OLIVIER JP, SAFAR M.E., Asmar, Rg, London, Gm, O'Rourke, Me, Mallion, Jm, Romero, R, Rahn, Kh, Trimarco, Bruno, Fitzgerald, D, Hedner, T, Duprez, D, DE LEEUW, Pw, Sever, P, Battegay, E, Hitzenberger, G, DE LUCA, Nicola, Polonia, P, Benetos, A, Chastang, C, Olivier, Jp, and Safar, M. E.
- Published
- 2001
8. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documental
- Author
-
Mancia, Giuseppe, Laurent, S, AGABITI ROSEI, Enrico, Ambrosioni, E, Burnier, M, Caulfield, Mj, Cifkova, R, Clément, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, Se, Kiowski, W, Mallion, Jm, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, Mh, Rahn, Kh, Redon, J, Rodicio, J, Ruilope, L, Schmieder, Re, Struijker Boudier HA, Van Zwieten PA, Viigimaa, M, and Zanchetti, A.
- Published
- 2009
9. ESH-ESC guidelines for the management of hypertension
- Author
-
Erdine, Serap, Ari, Oben, Zanchetti, A, Cifkova, R, Fagard, Robert, Kjeldsen, S, Mancia, G, Poulter, N, Rahn, KH, Rodicio, JL, Ruilope, LM, Staessen, Jan A, van Zwieten, P, Waeber, B, and Williams, B
- Subjects
Male ,medicine.medical_specialty ,Ambulatory blood pressure ,Systole ,Cardiology ,Secondary hypertension ,Risk Assessment ,Prehypertension ,Pharmacotherapy ,Sex Factors ,Diastole ,Risk Factors ,Diabetes mellitus ,medicine ,Humans ,Diabetic Nephropathies ,Intensive care medicine ,Exercise ,Life Style ,Antihypertensive Agents ,Societies, Medical ,Aged ,Dyslipidemias ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,business.industry ,Age Factors ,Blood Pressure Determination ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,medicine.disease ,Prognosis ,Diet ,Europe ,Blood pressure ,Diabetes Mellitus, Type 1 ,Diabetes Mellitus, Type 2 ,Emergency medicine ,Hypertension ,Aortic pressure ,Drug Therapy, Combination ,Female ,Kidney Diseases ,Cardiology and Cardiovascular Medicine ,Risk assessment ,business - Abstract
The following is a brief statement of the 2003 European Society of Hypertension (ESH)-European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. The continuous relationship between the level of blood pressure and cardiovascular risk makes the definition of hypertension arbitrary. Since risk factors cluster in hypertensive individuals, risk stratification should be made and decision about the management should not be based on blood pressure alone, but also according to the presence or absence of other risk factors, target organ damage, diabetes, and cardiovascular or renal damage, as well as on other aspects of the patient's personal, medical and social situation. Blood pressure values measured in the doctor's office or the clinic should commonly be used as reference. Ambulatory blood pressure monitoring may have clinical value, when considerable variability of office blood pressure is found over the same or different visits, high office blood pressure is measured in subjects otherwise at low global cardiovascular risk, there is marked discrepancy between blood pressure values measured in the office and at home, resistance to drug treatment is suspected, or research is involved. Secondary hypertension should always be investigated. The primary goal of treatment of patient with high blood pressure is to achieve the maximum reduction in long-term total risk of cardiovascular morbidity and mortality. This requires treatment of all the reversible factors identified, including smoking, dislipidemia, or diabetes, and the appropriate management of associated clinical conditions, as well as treatment of the raised blood pressure per se. On the basis of current evidence from trials, it can be recommended that blood pressure, both systolic and diastolic, be intensively lowered at least below 140/90 mmHg and to definitely lower values, if tolerated, in all hypertensive patients, and below 130/80 mmHg in diabetics. Lifestyle measures should be instituted whenever appropriate in all patients, including subjects with high normal blood pressure and patients who require drug treatment. The purpose is to lower blood pressure and to control other risk factors and clinical conditions present. In most, if not all, hypertensive patients, therapy should be started gradually, and target blood pressure achieved progressively through several weeks. To reach target blood pressure, it is likely that a large proportion of patients will require combination therapy with more than one agent. The main benefits of antihypertensive therapy are due to lowering of blood pressure per se. There is also evidence that specific drug classes may differ in some effect or in special groups of patients. The choice of drugs will be influenced by many factors, including previous experience of the patient with antihypertensive agents, cost of drugs, risk profile, presence or absence of target organ damage, clinical cardiovascular or renal disease or diabetes, patient's preference. ispartof: Herz vol:31 issue:4 pages:331-8 ispartof: location:Germany status: published
- Published
- 2006
10. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population--the seven European sites study (SESS)
- Author
-
Zimlichman, R, Shargorodsky, M, Boaz, M, Duprez, D, Rahn, Kh, Rizzoni, Damiano, Payeras, Ac, Hamm, C, and Mcveigh, G.
- Published
- 2005
11. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension
- Author
-
Lefrandt, JD, Heitmann, J, Sevre, K, Castellano, M, Hausberg, M, Fallon, M, Urbigkeit, A, Rostrup, M, Agabiti-Rosei, E, Rahn, KH, Murphy, M, Zannad, F, de Kam, PJ, Smit, AJ, Groningen Kidney Center (GKC), and Vascular Ageing Programme (VAP)
- Subjects
verapamil ,CALCIUM-ANTAGONISTS ,noradrenaline ,HEART ,BLOCKERS ,rate-pressure product ,BLOOD-PRESSURE ,amlodipine ,stress responses ,ISCHEMIA - Abstract
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascular,tress responses in hypertension. Methods One-hundred and forty-five patients with mild to moderate hypertension and a mean (+/- s.e.mean) age of 51 +/- 0.9 years received for 8 weeks the phenylalkylamine verapamil sustained release (240 mg) and the dihydropyridine amlodipine (5 mg) in a double-blind cross-over design, both after 4 weeks of placebo. Blood pressure, heart rate and plasma noradrenaline were monitored during 3 min of sustained isometric handgrip and 2 min of cold pressor. Results Blond pressure was equally reduced by both drugs. After 3 min handgrip, systolic blood pressure. heart rate and rate-pressure product were lower with verapamil compared with amlodipine. Verapamil attenuated the increases in systolic blood pressure (25 +/- 2 vs 30 +/- 2 mmHg, difference 4.6, 95% CI (1.0, 8.1), P
- Published
- 2001
12. How to assess glomerular function and damage in humans.
- Author
-
Rahn KH, Heidenreich S, Brückner D, Rahn, K H, Heidenreich, S, and Brückner, D
- Published
- 1999
- Full Text
- View/download PDF
13. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
- Author
-
Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid J, Rodicio J, Safar M, Eckes L, Ravinetto R, Zanchetti, A, Bond, M G, Hennig, M, Neiss, A, Mancia, G, and Dal Palù, C
- Published
- 1998
- Full Text
- View/download PDF
14. Vascular smooth muscle and striated heart muscle cell magnesium content in SHR.
- Author
-
Kisters, K, Krefting, ER, Barenbrock, M, Hausberg, M, and Rahn, KH
- Published
- 1999
- Full Text
- View/download PDF
15. Plasma and membrane Ca ++ and Mg ++ concentrations in normal pregnancy and in preeclampsia.
- Author
-
Kisters, K, Louwen, F, Witteler, R, Westermann, G, and Rahn, KH
- Published
- 1999
- Full Text
- View/download PDF
16. Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire.
- Author
-
Olsen MH, Mallion JM, Rahn KH, Erdine S, Viigimaa M, Laurent S, Agabiti-Rosei E, Mancia G, Schmieder RE, Cifkova R, Dominiczak A, Kjeldsen SE, Redon J, Zanchetti A, Nilsson P, Narkiewicz K, and ESH Council
- Published
- 2010
- Full Text
- View/download PDF
17. High blood pressure in pregnancy: effects of Ca2+ and Mg2+.
- Author
-
Kisters K, Louwen F, Witteler R, Hausberg M, Barenbrock M, and Rahn KH
- Published
- 1998
18. Sodium transport and exchange in spontaneously hypertensive rats.
- Author
-
Kisters K and Rahn KH
- Published
- 1999
19. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
- Author
-
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, Hansson, L, Zanchetti, A, Carruthers, S G, Dahlöf, B, Elmfeldt, D, Julius, S, Ménard, J, Rahn, K H, Wedel, H, and Westerling, S
- Abstract
Background: Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension.Methods: 18790 patients, from 26 countries, aged 50-80 years (mean 61.5 years) with hypertension and diastolic blood pressure between 100 mm Hg and 115 mm Hg (mean 105 mm Hg) were randomly assigned a target diastolic blood pressure. 6264 patients were allocated to the target pressure < or =90 mm Hg, 6264 to < or =85 mm Hg, and 6262 to < or =80 mm Hg. Felodipine was given as baseline therapy with the addition of other agents, according to a five-step regimen. In addition, 9399 patients were randomly assigned 75 mg/day acetylsalicylic acid (Bamycor, Astra) and 9391 patients were assigned placebo.Findings: Diastolic blood pressure was reduced by 20.3 mm Hg, 22.3 mm Hg, and 24.3 mm Hg, in the < or =90 mm Hg, < or =85 mm Hg, and < or =80 mm Hg target groups, respectively. The lowest incidence of major cardiovascular events occurred at a mean achieved diastolic blood pressure of 82.6 mm Hg; the lowest risk of cardiovascular mortality occurred at 86.5 mm Hg. Further reduction below these blood pressures was safe. In patients with diabetes mellitus there was a 51% reduction in major cardiovascular events in target group < or =80 mm Hg compared with target group < or =90 mm Hg (p for trend=0.005). Acetylsalicylic acid reduced major cardiovascular events by 15% (p=0.03) and all myocardial infarction by 36% (p=0.002), with no effect on stroke. There were seven fatal bleeds in the acetylsalicylic acid group and eight in the placebo group, and 129 versus 70 non-fatal major bleeds in the two groups, respectively (p<0.001).Interpretation: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events. The HOT Study shows the benefits of lowering the diastolic blood pressure down to 82.6 mm Hg. Acetylsalicylic acid significantly reduced major cardiovascular events with the greatest benefit seen in all myocardial infarction. There was no effect on the incidence of stroke or fatal bleeds, but non-fatal major bleeds were twice as common. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
20. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.
- Author
-
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, and Zanchetti A
- Subjects
- Europe, Humans, Hypertension physiopathology, Hypertension drug therapy, Practice Guidelines as Topic
- Published
- 2009
- Full Text
- View/download PDF
21. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension.
- Author
-
Kosch M, Levers A, Lang D, Bartels V, Rahn KH, Pavenstädt H, and Hausberg M
- Subjects
- Adult, Antihypertensive Agents pharmacology, Blood Flow Velocity physiology, Blood Pressure physiology, Dose-Response Relationship, Drug, Double-Blind Method, Elasticity, Female, Humans, Hypertension physiopathology, Male, Metoprolol pharmacology, Middle Aged, Sympathetic Nervous System physiology, Tetrazoles pharmacology, Tunica Intima diagnostic imaging, Tunica Media diagnostic imaging, Ultrasonography, Valine pharmacology, Valine therapeutic use, Valsartan, Antihypertensive Agents therapeutic use, Brachial Artery physiopathology, Carotid Arteries physiopathology, Endothelium, Vascular physiopathology, Hypertension drug therapy, Metoprolol therapeutic use, Tetrazoles therapeutic use, Valine analogs & derivatives
- Abstract
Background: Antihypertensive drugs may have differential, pressure-independent effects on hypertension-associated alterations of arterial function. We compared the effects of a 12-week therapy with the AT(1)-receptor antagonist valsartan (Val) versus the beta-blocker metoprolol (Met) on arterial stiffness and endothelial function in mildly hypertensive patients at rest and during generalized sympathetic stimulation., Methods: Sixty-eight patients (37 male, 31 female, 46 +/- 6 years) were randomized to Val (80-160 mg/d) or Met (50-100 mg/d). Effects of therapy on endothelial function, brachial and carotid artery distensibility coefficients, pulse wave velocity, carotid intima-media thickness and elastic modulus were assessed at rest and during the cold pressor test., Results: Fifty-two patients were available for per protocol analysis. Blood pressure was comparably reduced in both treatment groups. Effects on endothelial function and large artery elastic wall properties did not differ significantly between the two antihypertensive treatment regimens. Trends did not differ significantly between groups for any parameter including carotid intima-media thickness and elastic modulus., Conclusion: Short-term treatment with Val and Met had similar effects on large artery functional vessel wall properties in a population of mildly hypertensive patients.
- Published
- 2008
- Full Text
- View/download PDF
22. ACE inhibition after renal transplantation: the effect on persistent left ventricular hypertrophy.
- Author
-
Rahn KH
- Published
- 2008
- Full Text
- View/download PDF
23. ESH-ESC guidelines for the management of hypertension.
- Author
-
Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, and Williams B
- Subjects
- Age Factors, Aged, Aged, 80 and over, Antihypertensive Agents administration & dosage, Blood Pressure Determination, Blood Pressure Monitoring, Ambulatory, Cardiology, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 therapy, Diabetic Nephropathies prevention & control, Diastole, Diet, Drug Therapy, Combination, Dyslipidemias complications, Dyslipidemias therapy, Europe, Exercise, Female, Humans, Hypertension classification, Hypertension complications, Hypertension diagnosis, Hypertension drug therapy, Kidney Diseases complications, Kidney Diseases prevention & control, Kidney Diseases therapy, Life Style, Male, Middle Aged, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Sex Factors, Societies, Medical, Systole, Antihypertensive Agents therapeutic use, Hypertension therapy
- Abstract
The following is a brief statement of the 2003 European Society of Hypertension (ESH)-European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. The continuous relationship between the level of blood pressure and cardiovascular risk makes the definition of hypertension arbitrary. Since risk factors cluster in hypertensive individuals, risk stratification should be made and decision about the management should not be based on blood pressure alone, but also according to the presence or absence of other risk factors, target organ damage, diabetes, and cardiovascular or renal damage, as well as on other aspects of the patient's personal, medical and social situation. Blood pressure values measured in the doctor's office or the clinic should commonly be used as reference. Ambulatory blood pressure monitoring may have clinical value, when considerable variability of office blood pressure is found over the same or different visits, high office blood pressure is measured in subjects otherwise at low global cardiovascular risk, there is marked discrepancy between blood pressure values measured in the office and at home, resistance to drug treatment is suspected, or research is involved. Secondary hypertension should always be investigated. The primary goal of treatment of patient with high blood pressure is to achieve the maximum reduction in long-term total risk of cardiovascular morbidity and mortality. This requires treatment of all the reversible factors identified, including smoking, dislipidemia, or diabetes, and the appropriate management of associated clinical conditions, as well as treatment of the raised blood pressure per se. On the basis of current evidence from trials, it can be recommended that blood pressure, both systolic and diastolic, be intensively lowered at least below 140/90 mmHg and to definitely lower values, if tolerated, in all hypertensive patients, and below 130/80 mmHg in diabetics. Lifestyle measures should be instituted whenever appropriate in all patients, including subjects with high normal blood pressure and patients who require drug treatment. The purpose is to lower blood pressure and to control other risk factors and clinical conditions present. In most, if not all, hypertensive patients, therapy should be started gradually, and target blood pressure achieved progressively through several weeks. To reach target blood pressure, it is likely that a large proportion of patients will require combination therapy with more than one agent. The main benefits of antihypertensive therapy are due to lowering of blood pressure per se. There is also evidence that specific drug classes may differ in some effect or in special groups of patients. The choice of drugs will be influenced by many factors, including previous experience of the patient with antihypertensive agents, cost of drugs, risk profile, presence or absence of target organ damage, clinical cardiovascular or renal disease or diabetes, patient's preference.
- Published
- 2006
- Full Text
- View/download PDF
24. The role of calcium antagonists in patients with chronic renal failure.
- Author
-
Rahn KH
- Subjects
- Adolescent, Angiotensin II Type 1 Receptor Blockers pharmacology, Angiotensin-Converting Enzyme Inhibitors pharmacology, Calcium Channel Blockers pharmacology, Cardiovascular Diseases prevention & control, Child, Disease Progression, Humans, Kidney Failure, Chronic prevention & control, Renin-Angiotensin System drug effects, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Calcium Channel Blockers therapeutic use, Hypertension drug therapy, Kidney Failure, Chronic drug therapy
- Abstract
The objective of antihypertensive treatment in patients with chronic renal failure, many of whom have elevated blood pressure levels, is to reduce cardiovascular events and to slow down the progression of kidney function impairment. Calcium antagonists have been shown to be effective and safe antihypertensive drugs in patients from different age groups, including children. On the basis of numerous studies, one may conclude that the main benefit of antihypertensive therapy is because of the blood pressure lowering effect per se and that calcium antagonists do not differ from other antihypertensive drugs in the ability to prevent cardiovascular complications of hypertension. In particular, calcium antagonists are not inferior to other groups of antihypertensive agents in the prevention of coronary artery disease. There is, however, now evidence from controlled clinical trials that drugs interfering with the renin-angiotensin system are more beneficial than other antihypertensive agents in patients with chronic renal failure. Thus, several studies have demonstrated that ACE-inhibitors and, in patients with type-2 diabetic nephropathy, AT 1-antagonists are superior to other classes of antihypertensive drugs, including calcium antagonists, in delaying the progression of renal insufficiency. Therefore, in hypertensive patients with chronic renal failure antihypertensive treatment should be initiated with a drug that inhibits the renin-angiotensin system.
- Published
- 2005
- Full Text
- View/download PDF
25. Arterial distensibility, intima media thickness and pulse wave velocity after renal transplantation and in dialysis normotensive patients.
- Author
-
Posadzy-Malaczyñska A, Kosch M, Hausberg M, Rahn KH, Stanisic G, Malaczynski P, Gluszek J, and Tykarski A
- Subjects
- Blood Flow Velocity, Female, Humans, Kidney Failure, Chronic diagnostic imaging, Kidney Transplantation, Male, Middle Aged, Postoperative Period, Ultrasonography, Doppler, Pulsed, Carotid Artery, Common pathology, Kidney Failure, Chronic pathology, Renal Dialysis, Tunica Intima pathology
- Abstract
Aim: Structural and mechanical properties of the arterial wall are altered in patients with renal failure. The ageing process of the arterial wall appears to be accelerated in patients with end-stage renal failure. The mechanisms responsible for reduced arterial compliance and distensibility in dialysis patients and renal transplant recipients without hypertension remain to be evaluated., Methods: Thirty-five normotensive dialysis patients (D), 35 normotensive renal transplant recipients (T) and 35 healthy volunteers (N) matched for age, sex and blood pressure as controls were enrolled into the study. The arterial blood pressure of all patients was < 140/90 mmHg. The dialysis patients and renal transplant recipients were eligible for the study if the serum creatinine level was < 2 mg/dL. In all subjects, fasting concentrations of serum creatinine, total cholesterol, HDL-cholesterol, LDL-cholesterol and hemoglobin and glucose were determined at enrollment to the study. Blood pressure was measured using an automatic sphygmomanometer. Pulse wave velocity (PWV) was evaluated using non invasive automatic Complior device. The vessel wall properties of the left common carotid artery were studied using multigate pulsed Doppler system. With this method, the end-diastolic diameter (d) and the systolic increase of vessel diameter (distension DELTAd) were measured. From these data the relative systolic increase of vessel diameter (DELTAd/d) and the arterial wall distensibility coefficient (DC) were calculated., Results: Systolic blood pressure (SBP) and central pulse pressure (CPP) were significantly higher in T than in D and N group, respectively 138 +/- 18 mmHg and 59 +/- 16 mmHg vs 128 +/- 13 mmHg and 49 +/- 12 mmHg and 132.12 mmHg and 51 +/- 10 mmHg. The d did not change significantly between all groups. The distension DELTAd was significantly lower in patients group D and T, respectively 466 +/- 38 microm and 511 +/- 37 microm than in controls. Similarly DELTAd/d was in these groups significantly lower than in healthy volunteers, respectively D 6.33 +/- 0.5%, T 6.9 +/- 0.4% vs N 9.15 +/- 0.5%. DC was also significantly lower in D and T than in N groups, respectively D 17.91 +/- 1.5 10-3/kPa and T 18.92 +/- 1.3 10-3/kPa and N 24.28 +/- 0.51-3/kPa. Significant differences were found in the increase of the intima-media thickness (IMT) of carotid artery for dialyzed patients and renal transplant recipients in contrast to the control group, but there were no differences between the patients. PWV in both patient groups was statistically significant higher than in control group correspondingly D 11.1 +/- 1.03 m/s and T 13.3 +/- 1.13 m/s, N 9.4 +/- 0.89 m/s. There was a significant correlation between the change of DC, PWV and CPP in T group (n = 35; r = -0.43; P < 0.01 and n = 35; r = 0.48; P < 0.05). In the T group also an important correlation between PWV and IMT complex (n = 35; r = 0.49, P < 0.001) was found., Conclusions: The elastic and structural properties of arterial wall in dialysis patients and renal recipients are decreased. End-stage renal disease accelerates arterial stiffening despite of arteriosclerosis and hypertension. Renal transplantation does not reverse loss of elastic and morphologic properties of arteries found in patients with end-stage renal insufficiency.
- Published
- 2005
26. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population--the seven European sites study (SESS).
- Author
-
Zimlichman R, Shargorodsky M, Boaz M, Duprez D, Rahn KH, Rizzoni D, Payeras AC, Hamm C, and McVeigh G
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Compliance, Female, Follow-Up Studies, Heart Rate physiology, Humans, Male, Middle Aged, Myocardial Contraction physiology, Reference Values, Reproducibility of Results, Sex Factors, Statistics as Topic, Arteries physiology, Blood Pressure physiology
- Abstract
Background: We determined the reliability and repeatability of measurements of arterial compliance (AC) and gender- and age-specific normal ranges for a healthy European population., Methods: Three hundred eight healthy volunteers from seven sites were evaluated. Two measurements were taken during the first visit, repeated on a second visit 1 to 4 weeks later. We used the HDI/PulseWave CR-2000 for measurements of AC., Results: Intravisit measurements, taken 5 min apart, differed by less than 3% (range, 0.36% to 2.97%). All intervisit measures differed by less than 4% (range, 0.24% to 3.67%); none of these differences was statistically significant. All correlation coefficients for pairs of AC parameters measured 5 min apart at the same visit were significant at P < .0001. Paired AC parameters at visit 1 and 2 were highly correlated (P < .0001). Repeated measures GLM (general linear model) failed to detect a significant association between either of the AC parameters and visit (first or second), time (first or second measure at the same visit), and visit-by-time (the interaction of the two preceding factors), suggesting that order of measure had no effect on the final value. Analysis of reliability was used to develop a strictly parallel model estimate of unbiased reliability. Both intravisit and intervisit estimates of reliability indicate good repeatability of measure and were significant (P < .0001). The AC values were found to differ significantly by age group, with an inverse association between each of the AC parameters and age group., Conclusions: Measurement of the arterial waveform with the CR-2000 system is highly reproducible in healthy subjects.
- Published
- 2005
- Full Text
- View/download PDF
27. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.
- Author
-
de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, and Safar ME
- Subjects
- Adult, Aged, Antihypertensive Agents adverse effects, Atenolol administration & dosage, Blood Pressure drug effects, Brachial Artery, Drug Therapy, Combination, Echocardiography, Female, Humans, Hypertension diagnostic imaging, Hypertrophy, Left Ventricular diagnostic imaging, Indapamide adverse effects, Male, Middle Aged, Perindopril adverse effects, Antihypertensive Agents administration & dosage, Hypertension drug therapy, Hypertrophy, Left Ventricular drug therapy, Indapamide administration & dosage, Perindopril administration & dosage
- Abstract
Background: Increase in left ventricular mass (LVM) may be linked to morbidity and mortality in hypertensive patients. Arterial stiffness, systolic blood pressure (BP), and pulse pressure (PP) seem to be the main determinants of LVM. The perindopril/indapamide combination normalizes systolic BP, PP, and arterial function to a greater extent than atenolol. The aim of this study was to compare the effects of perindopril (2 mg)/indapamide (0.625 mg) first-line combination with atenolol (50 mg) on LVM reduction in hypertensive patients., Methods: Two hundred fourteen patients with essential hypertension participating in the PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd (REASON), randomized, double-blind, parallel-group study, underwent M-mode two-dimensional-guided echocardiography., Results: Perindopril/indapamide and atenolol were both effective at brachial BP reduction during the 12-month period. The systolic BP reduction was significantly greater with perindopril/indapamide than with atenolol (-21.2 v -15.3 mm Hg), whereas the reduction in diastolic BP was similar between treatment groups (-12.1 v -11.3 mm Hg). Reduction in LVM was higher with perindopril/indapamide than with atenolol. The between-group difference was significant for LVM (-13.6 v -4.3 g, P = .027), LVM/body surface area (LVMI1, P = .032), and LVM/body height2.7 (LVMI2, P = .013). The 124 patients with LV hypertrophy at baseline showed greatest LVM regression (LVM: -22.5 v -8.9 g, P = .009; LVMI1, P = .031; LVMI2, P = .028). The reduction in LVM adjusted for brachial systolic BP and heart rate was still significantly greater with perindopril/indapamide than with atenolol., Conclusions: Treatment, based on a first-line perindopril/indapamide combination in hypertensive patients, was more effective than atenolol on regression of echocardiographic indices of LVM and LV hypertrophy., (Copyright 2004 American Journal of Hypertension, Ltd.)
- Published
- 2004
- Full Text
- View/download PDF
28. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
- Author
-
Mallion JM, Chamontin B, Asmar R, De Leeuw PW, O'Brien E, Duprez D, O'Rourke MF, Rahn KH, Romero R, Battegay E, Hitzenberger G, and Safar ME
- Subjects
- Adrenergic beta-Antagonists adverse effects, Adrenergic beta-Antagonists therapeutic use, Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors adverse effects, Antihypertensive Agents adverse effects, Atenolol adverse effects, Atenolol therapeutic use, Diastole drug effects, Double-Blind Method, Drug Therapy, Combination, Europe epidemiology, Female, Heart Rate drug effects, Humans, Incidence, Indapamide adverse effects, Male, Middle Aged, Perindopril adverse effects, Systole drug effects, Treatment Outcome, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Blood Pressure Monitoring, Ambulatory, Circadian Rhythm drug effects, Hypertension drug therapy, Hypertension physiopathology, Indapamide therapeutic use, Perindopril therapeutic use
- Abstract
Background: Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension., Methods: A double-blind, randomized, controlled, 12-month study comparing perindopril/indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h., Results: After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/indapamide than for atenolol during the entire 24-h period (-13.8 v -9.2 mm Hg), the daytime and the nighttime periods (P <.01). Diastolic blood pressure (DBP) variations were comparable for the two groups (-7.2 v -8.3 mm Hg, NS). Pulse pressure (PP) reduction was also significantly greater for perindopril/indapamide than for atenolol (for the whole 24 h, -6.6 v -0.9 mm Hg, P <.001). The through to peak (T/P) BP ratio and the smoothness index were comparable in the two groups for DBP. For systolic blood pressure (SBP), higher values of the T/P ratio (0.80 v 0.59) and the smoothness index (1.45 v 0.98; P <.02) were achieved for the perindopril/indapamide combination than for atenolol., Conclusions: The perindopril/indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol.
- Published
- 2004
- Full Text
- View/download PDF
29. Vasoactivity of diadenosine polyphosphates in human small renal resistance arteries.
- Author
-
Steinmetz M, Gabriëls G, Le TV, Piechota HJ, Rahn KH, and Schlatter E
- Subjects
- Hemodynamics physiology, Humans, In Vitro Techniques, Kidney drug effects, Kidney physiopathology, Purinergic Antagonists, Renal Artery physiology, Vascular Resistance drug effects, Vasoconstriction drug effects, Vasodilation drug effects, Adenine Nucleotides pharmacology, Adenosine pharmacology, Dinucleoside Phosphates pharmacology, Hemodynamics drug effects, Kidney blood supply, Renal Artery drug effects
- Abstract
Background: We examined for the first time the vascular effects of purinergic agents that contribute to the regulation of peripheral vascular resistance in human small renal resistance arteries (hRRAs)., Methods and Results: Diadenosine polyphosphates (ApnAs, n = 3-6) and ATP, mounted in a microvessel myograph, caused vasoconstriction in hRRAs (rank order of potency: Ap5A > Ap6A = Ap4A > Ap3A = ATP). ADP, AMP and adenosine had less contractile potency than ApnA, suggesting that the observed effects were not induced by ApnA degradation products. The ApnA agent, Ap5A, but not Ap4A, induced vasoconstrictions that were inhibited by pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS; a P2X purinoceptor antagonist), but not by ADP3'5' (a P2Y purinoceptor antagonist). In pre-contracted hRRAs, all of the ApnA agents caused vasorelaxation, and the potencies did not differ from each other. The ApnA degradation products had less vasorelaxing potencies than ApnA, suggesting that the vasorelaxation was caused by the ApnA agents themselves. Ap4A-induced vasorelaxation was inhibited by ADP3'5' and PPADS. In contrast, Ap5A-induced vasorelaxation was not antagonized by ADP3'5', but was antagonized more strongly by PPADS than was Ap4A., Conclusions: We found that the tone of resistance arteries in human kidneys can be considerably influenced by these purinergic agonists, and most potently by ApnAs. Ap5A-induced vasoconstriction appeared to be mediated by P2X purinoceptors, whereas constriction due to Ap4A was caused by a different purinoceptor. Vasorelaxation due to Ap4A, but not Ap5A, appeared to be mediated by P2Y purinoceptors.
- Published
- 2003
- Full Text
- View/download PDF
30. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines.
- Author
-
Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Lüscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, and Zanchetti A
- Subjects
- Humans, Hypertension diagnosis, Antihypertensive Agents therapeutic use, Hypertension drug therapy, Primary Health Care standards
- Published
- 2003
- Full Text
- View/download PDF
31. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress.
- Author
-
Kosch M, Levers A, Fobker M, Barenbrock M, Schaefer RM, Rahn KH, and Hausberg M
- Subjects
- Acute Disease, Adult, Brachial Artery physiopathology, Cardiovascular Diseases prevention & control, Cross-Over Studies, Double-Blind Method, Female, Humans, Kidney Failure, Chronic complications, Male, Middle Aged, Biocompatible Materials therapeutic use, Cardiovascular Diseases etiology, Cardiovascular Diseases physiopathology, Cellulose analogs & derivatives, Cellulose therapeutic use, Endothelium, Vascular physiopathology, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic therapy, Membranes, Artificial, Oxidative Stress physiology, Polymers therapeutic use, Renal Dialysis adverse effects, Sulfones therapeutic use
- Abstract
Background: Endothelial function of large arteries is impaired in chronic haemodialysis patients and oxidative stress due to the dialysis procedure has been suggested as a causal factor. However, it is not clear whether different types of dialysis membranes affect endothelial function differently. Therefore we determined endothelium-dependent, flow-mediated dilatation (FMD) of the brachial artery as well as markers of oxidative stress immediately before and after haemodialysis (HD) with either a cellulosic cuprophane or a synthetic polysulphone dialyser in a blinded, randomized, cross-over study., Methods: Twelve haemodialysis patients (age 55+/-3 years, time on dialysis 20+/-2 months, mean fluid change -1782+/-21 ml, systolic/diastolic blood pressure 139/75 mmHg) were included. Using a multi-gate-pulsed Doppler system (echo-tracking device) brachial artery FMD and nitroglycerine-induced, endothelium-independent vasodilatation (NMD) were measured. Patients were randomized to HD with either a polysulphone or a cuprophane membrane and were crossed over to the other filter. Investigators were blinded to the type of membrane used. Serum concentrations of oxidized LDL (oxLDL) and alpha-tocopherol as markers of oxidative stress were measured before and after each dialysis session., Results: Data are given as mean+/-SEM. Treatment with polysulphone filter HD did not significantly affect FMD (baseline 9.3+/-2.0% vs after HD 9.6+/-1.8%). After dialysis with a cuprophane membrane FMD decreased from 9.4+/-2.1 to 7.4+/-1.8% (P<0.05). NMD was not significantly affected by HD irrespective of the membrane material used. Serum levels of oxLDL were not changed by either treatment; however, alpha-tocopherol concentrations fell significantly after dialysis with the cuprophane filter (baseline 18.0+/-2.3 after HD 16.6+/-1.3 micro g/ml, P<0.05), while alpha-tocopherol levels remained unchanged when the polysulphone membrane was used., Conclusions: The type of dialysis filter membrane determines the acute effect of haemodialysis on arterial endothelial function. Differences in biocompatibility and oxidative stress may account for the observed differential effects, since the decrease of FMD after dialysis with a cellulosic cuprophane membrane-but not with a synthetic polysulphone membrane-was associated with a reduction in serum vitamin E.
- Published
- 2003
- Full Text
- View/download PDF
32. The parathyroid hormone-2 receptor is expressed on human leukocytes and down-regulated in hyperparathyroidism.
- Author
-
Seeliger S, Hausberg M, Eue I, Usdin T, Rahn KH, and Kosch M
- Subjects
- Adult, Animals, Case-Control Studies, Down-Regulation, Female, Flow Cytometry, Humans, Immunohistochemistry, Male, Rabbits, Receptor, Parathyroid Hormone, Type 2, Hyperparathyroidism metabolism, Leukocytes metabolism, Receptors, Parathyroid Hormone metabolism
- Abstract
Background: Parathyroid hormone (PTH) has specific effects on function, migration and proliferation of human leukocytes. These effects may contribute to accelerated atherosclerosis and impaired immune response observed in patients with renal insufficiency. Recently, a new G protein-coupled receptor with substantial implications for vascular function--the PTH2 receptor (PTH2-R)--has been identified, however, expression and distribution in humans and a possible regulation has not yet been studied. We therefore investigated the expression of the PTH2 receptor on human leukocytes in healthy subjects and in patients with hyperparathyroidism., Methods: PTH2 receptor expression was quantified by flow cytometry (FACS) analysis on monocytes, lymphocytes and granulocytes that were isolated from peripheral blood (hypotonic density gradient centrifugation) and by immunohistochemistry using a specific alpha-PTH2-R antibody produced in rabbit. Results of 22 patients with hyperparathyroidism (12 renal allograft recipients, 10 hemodialysis patients, mean age 43 +/- 8 years) were compared to 22 age and sex-matched healthy controls., Results: Mean relative antigen density of the PTH2 receptor and percentage of positive cells in healthy subjects was 19 +/- 5 and 90 +/- 6% on granulocytes, 5 +/- 2 and 55 +/- 19% on monocytes, and 24 +/- 7 and 21 +/- 7% on lymphocytes. In patients with hyperparathyroidism, mean antigen density was significantly lower on granulocytes and monocytes (17 +/- 4% and 3 +/- 1%, p < 0.01, respectively). The percentage of positive cells and mean expression on lymphocytes was not significantly different. A significant and inverse correlation was found between plasma PTH concentrations and the mean PTH2 receptor expression on granulocytes (r = -0.41, p < 0.05)., Conclusions: The PTH2 receptor is expressed on human granulocytes and--to a lesser degree--on monocytes and lymphocytes. In patients with hyperparathyroidism the PTH2 receptor is down-regulated as function of plasma PTH levels.
- Published
- 2003
- Full Text
- View/download PDF
33. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
- Author
-
Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, and Hohage H
- Subjects
- Adult, Blood Pressure drug effects, Female, Follow-Up Studies, Hemoglobins, Humans, Immunosuppression Therapy, Kidney physiology, Male, Prospective Studies, Quinapril, Transplantation, Homologous, Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Atenolol therapeutic use, Hypertension, Renal drug therapy, Kidney Transplantation, Tetrahydroisoquinolines therapeutic use
- Abstract
Hypertension and nephrotoxicity are frequent complications of cyclosporine-induced immunosuppression in renal transplant recipients. Long-term antihypertensive treatment is obligatory for hypertensive transplant patients, to protect allograft function. The use of angiotensin-converting enzyme (ACE) inhibitors in the anti-hypertensive treatment of renal transplant recipients who receive immunosuppression with cyclosporine has long been discussed controversially. The aim of this prospective study, with a duration of 2 years and a follow-up of another 3 years, was to estimate the long-term antihypertensive potential of quinapril compared with that of the beta-blocker atenolol and to compare their effects on renal allograft function and proteinuria in 96 hypertensive renal transplant recipients who received cyclosporine A as immunosuppressive therapy. Patients were randomly assigned to receive either quinapril (group Q) or atenolol (group A) as anti-hypertensive treatment. Forty patients of each group completed the 5-year observation period according to protocol. Intention-to-treat and according-to-protocol analyses were performed. With the patients starting at similar baseline blood pressure values, both agents, atenolol and quinapril, decreased systolic and diastolic blood pressure (SBP, DBP) as well as middle arterial pressure (MAP) and pulse pressure (PP) to a similar extent (Delta SBP: group Q: -8+/-3 vs group A mmHg: -5+/-3; Delta DBP: -5+/-2 vs -4+/-2 mmHg; Delta MAP: -6+/-2 vs -5+/-2 mmHg; Delta PP: -2+/-2 vs -1+/-3 mmHg; mean +/- SEM). Neither serum creatinine levels nor Cockcroft-Gault clearance had changed significantly in either group after the 5-year period (Delta creatinine: 0.1+/-0.1 vs 0.2+/-0.2 mg/dl; Delta Cockcroft-Gault clearance: 3.9+/-4.6 vs 2.8+/-4.3 ml/min; mean +/- SEM). Urinary protein excretion remained stable among the quinapril-treated patients, whereas a significant increase was observed in the atenolol group during the 5-year study period (group Q: from 0.52+/-0.08 to 0.54+/-0.14 g/24 h; group A: from 0.34+/-0.03 to 0.72+/-0.13 g/24 h, P<0.02; mean +/- SEM). Albuminuria increased comparably in both groups, while the excretion of alpha-microglobuline increased slightly in the atenolol group, but decreased slightly in the quinapril group. The difference between the groups failed to be statistically significant (ANOVA, P<0.056). In conclusion, quinapril and atenolol may be considered suitable and safe substances in the long-term treatment of hypertensive renal transplant recipients, since both agents prove to be effective in anti-hypertensive treatment, and keep allograft function stable over a period of 5 years.
- Published
- 2003
- Full Text
- View/download PDF
34. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
- Author
-
Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, and Hausberg M
- Subjects
- Anticholesteremic Agents therapeutic use, Brachial Artery physiology, Carotid Artery, Common physiology, Endothelium, Vascular physiology, Fatty Acids, Monounsaturated therapeutic use, Female, Fluvastatin, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia physiopathology, Indoles therapeutic use, Kidney Transplantation, Male, Middle Aged, Prospective Studies, Anticholesteremic Agents pharmacology, Endothelium, Vascular drug effects, Fatty Acids, Monounsaturated pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hypercholesterolemia drug therapy, Indoles pharmacology, Vasodilation drug effects
- Abstract
Background: In patients after renal transplantation functional arterial vessel wall properties are impaired. Whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have a sustained effect on endothelial function and arterial distensibility in patients after renal transplantation is not clear. The authors studied the effects of a long-term therapy with fluvastatin on large artery distensibility and flow-mediated vasodilation (FMD) in hypercholesterolemic patients after renal transplantation in a prospective, blinded, and randomized trial., Methods: Twenty-six patients who had undergone renal transplantation were assigned randomly to either fluvastatin, 40 mg/d (n = 13) or placebo (n = 13) and underwent follow-up for 3 years. At baseline and after 6, 12, and 36 months of treatment, carotid and brachial artery distensibility, endothelium-dependent FMD, and nitroglycerine-induced vasodilation (NMD) of the brachial artery were measured by a echo-tracking device., Results: A significant decrease in total and low-density cholesterol was observed after 6, 12, and 36 months in patients treated with fluvastatin but not in the placebo group. FMD increased with fluvastatin from 4.6 +/- 2% to 12.4 +/- 2% after 12 months; this improvement was sustained with 13.4 +/- 3% after 36 months (P < 0.05). However, placebo did not alter FMD (P < 0.001 for trend difference between groups by analysis of covariance). Endothelium-independent NMD was similar in both groups at baseline and during therapy. Neither carotid nor brachial artery distensibility coefficients were altered by either treatment., Conclusion: HMG-CoA reductase inhibitor therapy over 3 years results in a significant and sustained improvement of endothelial function in hypercholesterolemic patients after renal transplantation. However, this is not accompanied by a beneficial effect on impaired large artery distensibility even after long-term therapy with fluvastatin.
- Published
- 2003
- Full Text
- View/download PDF
35. Impact of renal transplantation on small vessel reactivity.
- Author
-
Gabriëls G, August C, Grisk O, Steinmetz M, Kosch M, Rahn KH, and Schlatter E
- Subjects
- Angiotensin II pharmacology, Animals, Arginine Vasopressin pharmacology, Arteries, Blood Vessels drug effects, Blood Vessels physiopathology, Coronary Vessels physiopathology, Femoral Artery physiopathology, Kidney pathology, Male, Mesenteric Arteries physiopathology, Microcirculation, Norepinephrine pharmacology, Phenylephrine pharmacology, Rats, Rats, Inbred F344, Vascular Resistance, Vasoconstrictor Agents pharmacology, Kidney Transplantation, Renal Circulation
- Abstract
Background: The function of large arteries is altered after renal transplantation. Whether transplantation also induces agonist-dependent functional changes in small arterial renal and extrarenal vessels has not yet been studied., Methods: Chronic rejection was induced by grafting Lewis rats with kidneys from Fischer rats (FL). Rats that underwent transplantation were bilaterally nephrectomized. Rats that underwent syngeneic transplantation, uninephrectomized rats, uninephrectomized rats with denervated kidneys or with kidneys made ischemic, and native rats served as controls. All animals were treated with cyclosporine for 10 days. Eighteen weeks after surgery, the reactivity of small arteries (220-270 microm) was tested by myography., Results: Weight gain, glomerular filtration rate, and arterial pressure were similar in all groups, whereas proteinuria was elevated in FL. Only kidneys from FL showed glomerular lesions, tubular atrophy, and vasculopathy. Responsiveness of coronary, mesenteric, and femoral resistance vessels to both constrictor and dilator agonists was similar in transplanted and nontransplanted animals. Resistance vessels obtained from both allogeneically and syngeneically transplanted kidneys were more sensitive to norepinephrine, phenylephrine, angiotensin II, and vasopressin than renal vessels from weight-matched controls. Vasodilation in response to acetylcholine and sodium nitroprusside was mitigated in transplanted versus nontransplanted kidneys., Conclusions: In rat renal transplantation, renal resistance vessel responsiveness to constrictor or dilator stimuli is altered. Extrarenal small vessel function is not affected. The changes in function of renal resistance vessels are not explained by reduction of nephron mass, denervation, ischemia, or chronic rejection.
- Published
- 2003
- Full Text
- View/download PDF
36. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
- Author
-
Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, and Rizzini P
- Subjects
- Aged, Aged, 80 and over, Antihypertensive Agents adverse effects, Atenolol adverse effects, Atenolol pharmacology, Blood Pressure drug effects, Calcium Channel Blockers adverse effects, Carotid Arteries diagnostic imaging, Carotid Arteries drug effects, Carotid Artery Diseases complications, Carotid Artery Diseases diagnostic imaging, Dihydropyridines adverse effects, Disease Progression, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heart Rate drug effects, Humans, Hypertension complications, Male, Middle Aged, Time, Treatment Outcome, Tunica Intima diagnostic imaging, Tunica Intima drug effects, Tunica Media diagnostic imaging, Tunica Media drug effects, Ultrasonography, Antihypertensive Agents pharmacology, Calcium Channel Blockers therapeutic use, Carotid Artery Diseases drug therapy, Dihydropyridines therapeutic use, Hypertension drug therapy
- Abstract
Background: Most cardiovascular events associated with hypertension are complications of atherosclerosis. Some antihypertensive agents influence experimental models of atherosclerosis through mechanisms independent of blood pressure lowering., Methods and Results: The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in far walls of common carotids and bifurcations (CBM(max)). This index has been shown by epidemiological studies to be predictive of cardiovascular events. A significant (P<0.0001) effect of lacidipine was found compared with atenolol, with a treatment difference in 4-year CBM(max) progression of -0.0227 mm (intention-to-treat population) and -0.0281 mm (completers). The yearly IMT progression rate was 0.0145 mm/y in atenolol-treated and 0.0087 mm/y in lacidipine-treated patients (completers, 40% reduction; P=0.0073). Patients with plaque progression were significantly less common, and patients with plaque regression were significantly more common in the lacidipine group. Clinic blood pressure reductions were identical with both treatments, but 24-hour ambulatory systolic/diastolic blood pressure changes were greater with atenolol (-10/-9 mm Hg) than with lacidipine (-7/-5 mm Hg). No significant difference between treatments was found in any cardiovascular events, although the relative risk for stroke, major cardiovascular events, and mortality showed a trend favoring lacidipine., Conclusion: The greater efficacy of lacidipine on carotid IMT progression and number of plaques per patient, despite a smaller ambulatory blood pressure reduction, indicates an antiatherosclerotic action of lacidipine independent of its antihypertensive action.
- Published
- 2002
- Full Text
- View/download PDF
37. Sympathetic nerve activity in end-stage renal disease.
- Author
-
Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, and Rahn KH
- Subjects
- Calcineurin Inhibitors, Cyclosporine therapeutic use, Female, Hemodynamics, Humans, Hypertension physiopathology, Immunosuppressive Agents therapeutic use, Kidney physiopathology, Kidney Failure, Chronic drug therapy, Kidney Failure, Chronic surgery, Male, Middle Aged, Muscle, Skeletal innervation, Nephrectomy, Renal Dialysis, Tacrolimus therapeutic use, Uremia surgery, Kidney Failure, Chronic physiopathology, Kidney Transplantation, Sympathetic Nervous System physiopathology
- Abstract
Background: Uremia is proposed to increase sympathetic nerve activity (SNA) in hemodialysis patients. The aims of the present study were to determine whether reversal of uremia by successful kidney transplantation (RTX) eliminates the increased SNA and whether signals arising in the diseased kidneys contribute to the increased SNA in renal failure., Methods and Results: We compared muscle sympathetic nerve activity (MSNA) in 13 hemodialysis patients wait-listed for RTX and in renal transplantation patients with excellent graft function treated with cyclosporine (RTX-CSA, n=13), tacrolimus (RTX-FK, n=13), or without calcineurin inhibitors (RTX-Phi, n=6), as well as in healthy volunteers (CON, n=15). In addition to the above patients with present diseased native kidneys, we studied 16 RTX patients who had undergone bilateral nephrectomy (RTX-NE). Data are mean+/-SEM. MSNA was significantly elevated in hemodialysis patients (43+/-4 bursts/min), RTX-CSA (44+/-5 bursts/min), RTX-FK (34+/-3 bursts/min), and RTX-Phi (44+/-5 bursts/min) as compared with CON (21+/-3 bursts/min), despite excellent graft function after RTX. RTX-NE had significantly reduced MSNA (20+/-3 bursts/min) when compared with RTX patients. MSNA did not change significantly with RTX in 4 hemodialysis patients studied before and after RTX (44+/-6 versus 43+/-5 bursts/min, P=NS). In contrast, nephrectomy resulted in reduced MSNA in all 6 RTX patients studied before and after removal of the second native kidney., Conclusions: Despite correction of uremia, increased SNA is observed in renal transplant recipients with diseased native kidneys at a level not significantly different from chronic hemodialysis patients. The increased SNA seems to be mediated by signals arising in the native kidneys that are independent of circulating uremia related toxins.
- Published
- 2002
- Full Text
- View/download PDF
38. Mesenteric and renal vascular effects of diadenosine polyphosphates (APnA).
- Author
-
Gabriëls G, Rahn KH, Schlatter E, and Steinmetz M
- Subjects
- Animals, Forearm blood supply, Hemodynamics drug effects, Humans, In Vitro Techniques, Microcirculation drug effects, Muscle, Smooth, Vascular drug effects, Muscle, Smooth, Vascular metabolism, Perfusion, Rabbits, Rats, Receptors, Purinergic P2 drug effects, Receptors, Purinergic P2 metabolism, Dinucleoside Phosphates pharmacology, Mesenteric Arteries drug effects, Renal Artery drug effects, Vasodilator Agents pharmacology
- Abstract
Diadenosine polyphosphates (APnA) are endogenous dinucleoside molecules consisting of two adenosine moieties linked via their 5'-ribose positions by a variable number of phosphate groups. APnA have been shown to be present in different cell types and to be released from platelets as well as co-released with catecholamines and ATP from bovine adrenal medulla. Candidate metabolites of APnA are ATP, ADP, AMP and adenosine. Vascular effects induced by APnA and their metabolites in several models have been reported to be mediated by A1- and A2-adenosine receptors as well as P2-purinoceptors. APnA have been demonstrated to differentially affect regional perfusion, to influence cardiac output and blood pressure as well as the reactivity of isolated blood vessels and vascular beds. Vascular effects of APnA vary with the number of phosphate groups linking the adenosine molecules. This review outlines the effects of APnA on mesenteric and renal circulation. The effects of the antagonists varying with the type of vascular bed and the heterogeneous and dynamic vascular effects of diadenosine polyphosphates indicate a regionally different distribution of P2X and of P2Y purinoceptors in resistance arteries from different vascular beds. Although APnA have vasoconstrictor effects on the local level, it was repeatedly confirmed that systemically applied APnA induce hypotensive effects. The vasoconstrictor effects of APnA in isolated vessels are most prominent under resting tone conditions. In vivo, the vasculature exhibits a vasotone which makes dilatory effects more likely. Information on effects of APnA in vivo is still limited despite the fact that these compounds already have been used in man.
- Published
- 2002
- Full Text
- View/download PDF
39. Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries.
- Author
-
Steinmetz M, Janssen AK, Pelster F, Rahn KH, and Schlatter E
- Subjects
- Animals, Humans, In Vitro Techniques, Kinetics, Mesenteric Arteries drug effects, Rats, Dinucleoside Phosphates pharmacology, Mesenteric Arteries physiology, Muscle Contraction drug effects, Vascular Resistance drug effects
- Abstract
Diadenosine polyphosphates (ApnA) (n = 3-6) induced vasoconstrictions in isolated human mesenteric resistance arteries (hMRAs) mounted in a microvessel myograph (rank order of potency: Ap5A > Ap6A > Ap4A > Ap3A). The contractile effects of ApnA in hMRA were similar to their effects in rat MRA investigated previously. ATP, ADP, AMP, and adenosine had less contractile potency than ApnA, suggesting that the observed effects were not induced by the degradation products of ApnA. Ap4A- and Ap5A-induced vasoconstriction was inhibited by pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (P2X purinoceptor antagonist) but not by ADP3'5' (P2Y purinoceptor antagonist). Thus, this purinergic vasoconstriction of hMRA seems to be P2X but not P2Y purinoceptor-mediated. In precontracted hMRA all ApnA caused vasorelaxations but (in contrast to rat MRA) the potencies of the ApnA did not differ significantly from each other. The ApnA degradation products had less vasorelaxing potency than ApnA, demonstrating that the vasorelaxations can be ascribed to the ApnA themselves. Ap5A-induced vasorelaxation of hMRA could neither be inhibited with ADP3'5' nor with PPADS, which reveals a decisive difference to the rat MRA where the inhibitory profile demonstrated the importance of the P2Y purinoceptor for Ap5A-induced vasorelaxation. However, Ap4A-induced vasorelaxation in hMRA could be inhibited by ADP3'5'. These findings show that Ap4A-induced vasorelaxation in hMRA is due to P2Y purinoceptor activation, that Ap5A evokes vasorelaxation in hMRA via another mechanism than Ap4A, and that data derived from the animal model cannot be simply transferred to human conditions.
- Published
- 2002
- Full Text
- View/download PDF
40. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.
- Author
-
Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, and Wedel H
- Subjects
- Aged, Aspirin therapeutic use, Cardiovascular System drug effects, Diastole, Dose-Response Relationship, Drug, Double-Blind Method, Drug Interactions, Female, Humans, Kidney drug effects, Male, Middle Aged, Platelet Aggregation Inhibitors pharmacology, Systole, Antihypertensive Agents therapeutic use, Aspirin administration & dosage, Blood Pressure drug effects, Cardiovascular Diseases prevention & control, Hypertension drug therapy, Platelet Aggregation Inhibitors administration & dosage
- Abstract
Background: It has been reported that aspirin (ASA) may interfere with the blood pressure (BP)-lowering effect of various antihypertensive agents and attenuate the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure., Methods and Results: Data from the Hypertension Optimal Treatment (HOT) Study, in which 18 790 intensively treated hypertensive patients were randomized to either ASA 75 mg daily or placebo for 3.8 years (with a 15% reduction in cardiovascular events and a 36% reduction in myocardial infarction in ASA-treated patients), were reanalysed for the whole group of patients and for various subgroups with particular attention to the possible effects of ASA on BP and renal function. In ASA-treated and placebo-treated patients: (1) systolic blood pressure (SBP) and diastolic blood pressure (DBP) values achieved with antihypertensive treatment were superimposable, with clinically irrelevant differences; (2) these superimposable SBP and DBP were achieved with antihypertensive therapies, that were quantitatively and qualitatively similar, and (3) changes in serum creatinine and in estimated creatinine clearance and the number of patients developing renal dysfunction were also similar. Furthermore, the cardiovascular benefits of ASA were of the same magnitude in hypertensive patients receiving or not receiving ACE-inhibitors., Conclusions: Even long-term, low-dose ASA does not interfere with the BP-lowering effect of antihypertensive agents, including combinations with ACE inhibitors, or with renal function. No negative interaction occurs between ACE inhibition and the cardiovascular benefits of small dose of ASA. Our conclusions cannot be extended to larger doses of ASA, or to patients with congestive heart failure.
- Published
- 2002
- Full Text
- View/download PDF
41. Calcium, hypertension and loss of Bone mineral density in women.
- Author
-
Kisters K, Kosch M, Rahn KH, and Hausberg M
- Subjects
- Female, Humans, Bone Density, Calcium metabolism, Hypertension metabolism
- Published
- 2002
- Full Text
- View/download PDF
42. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients.
- Author
-
Kosch M, Barenbrock M, Kisters K, Rahn KH, and Hausberg M
- Subjects
- Adult, Azathioprine therapeutic use, Calcineurin Inhibitors, Cyclosporine therapeutic use, Elasticity, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Nephrectomy, Postoperative Period, Reference Values, Tacrolimus therapeutic use, Brachial Artery physiopathology, Carotid Artery, Common physiopathology, Kidney Transplantation, Muscles innervation, Sympathetic Nervous System physiopathology, Vasomotor System physiopathology
- Abstract
Objectives: Renal transplant recipients (RTX) show a major impairment of large artery elastic wall properties. Sympathetic overactivity present in patients with renal disease has been shown to alter large artery elasticity; however, in RTX, this issue has not been addressed. The present study therefore investigated a possible relationship between sympathetic activity and large artery distensibility in RTX., Methods: In 32 patients treated with calcineurin inhibitors (RTX-CI, cyclosporine n = 16, tacrolimus n = 16) mean arterial pressure (MAP, automatic sphygmomanometer), muscle sympathetic nerve activity (MSNA, microneurography) and distensibility coefficients of the brachial and carotid arteries (pulsed Doppler) were measured. Sixteen healthy volunteers (CTR), six patients with calcinneurin inhibitor-free immunosuppression (RTX-AZA) and 12 transplant patients after native kidney nephrectomy (RTX-NC) served as control groups., Results: RTX-CI significantly increased MSNA compared to CTR (36 +/- 3 versus 16 +/- 2 bursts/min, P < 0.05, mean +/- SEM). Both brachial and carotid artery distensibility were decreased in RTX-CI compared to CTR (7 +/- 1 versus 13 +/- 1 +/- 10(-3) /kPa and 17 +/- 1 versus 25 +/- 2 x 10(-3) /kPa, respectively, both P < 0.05). In RTX-CI, a significant inverse correlation between brachial, but not carotid artery distensibility and MSNA (r = -0.46, P < 0.01, r = -0.12, not significant, respectively) was found. Correlation between brachial artery distensibility and MSNA remained statistically significant on separate analysis of cyclosporine- or tacrolimus-treated RTX and after correction for arterial diameter, blood pressure, graft function, age and sex by stepwise multiple regression analysis. Results in RTX-AZA were similar to those in RTX-CI. In contrast, in RTX-NC with MSNA not significantly different from CON (16.6 +/- 2.0 bursts/min), brachial artery distensibility was significantly higher compared to RTX-CI and RTX-AZA (14.2 +/- 2.0 x 10(-3) /kPa, P < 0.05, respectively)., Conclusions: Increased sympathetic nerve activity in renal transplant patients is related to decreased distensibility of the muscular type brachial artery, but not the elastic type carotid artery.
- Published
- 2002
- Full Text
- View/download PDF
43. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation.
- Author
-
Barenbrock M, Kosch M, Jöster E, Kisters K, Rahn KH, and Hausberg M
- Subjects
- Adolescent, Adult, Age Factors, Blood Pressure physiology, Cardiovascular Diseases blood, Cholesterol blood, Creatinine blood, Female, Follow-Up Studies, Germany epidemiology, Heart Rate physiology, Humans, Male, Middle Aged, Postoperative Complications etiology, Postoperative Complications physiopathology, Predictive Value of Tests, Prospective Studies, Renal Dialysis, Sex Factors, Cardiovascular Diseases etiology, Carotid Artery, Common physiopathology, Kidney Transplantation
- Abstract
Objective: Arterial distensibility is reduced in end-stage renal failure and also after renal transplantation. The aim of the present study was to test the hypothesis that reduced carotid artery distensibility is a predictor of cardiovascular disease in patients after renal transplantation., Subjects and Methods: Sixty-eight asymptomatic renal transplant recipients were studied between March 1990 and December 1992, 3-6 months after transplantation. The mean duration of follow-up was 95 +/- 2 months (mean +/- SEM). At entry, vessel wall movements of the common carotid artery were recorded using a pulsed multigate Doppler system; blood pressure was measured by sphygmomanometry., Results: Nineteen cardiovascular events (CVE) occurred during follow-up, leading to death in six cases. The distensibility coefficient of the common carotid artery was significantly lower in patients with CVE than in those without CVE (12.2 +/- 1.0 10-3/kPa versus 16.8 +/- 0.7 10-3/kPa, P < 0.005). Logistic regression analysis showed that the occurrence of cardiovascular disease during follow-up was related to carotid artery distensibility (P < 0.05), independent of sex, age, smoking habits, carotid artery end-diastolic diameter, systolic and diastolic blood pressure levels, heart rate, serum creatinine, cholesterol and haemoglobin levels. Patients with a distensibility coefficient above the age-adjusted mean had a significantly longer interval free of cardiovascular disease than patients with a distensibility coefficient below the age-adjusted mean (P < 0.01)., Conclusions: The distensibility of the common carotid artery is an independent predictor of cardiovascular disease in renal transplant recipients.
- Published
- 2002
- Full Text
- View/download PDF
44. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension.
- Author
-
Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Urbigkeit A, Rostrup M, Agabiti-Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, and Smit AJ
- Subjects
- Adult, Aged, Amlodipine administration & dosage, Amlodipine blood, Blood Pressure drug effects, Calcium Channel Blockers blood, Cross-Over Studies, Double-Blind Method, Exercise Test, Female, Heart Rate drug effects, Hemodynamics drug effects, Humans, Hypertension physiopathology, Male, Middle Aged, Norepinephrine blood, Sphygmomanometers, Verapamil blood, Amlodipine therapeutic use, Calcium Channel Blockers therapeutic use, Hypertension drug therapy, Verapamil therapeutic use
- Abstract
Aims: To compare the effects of two long-acting calcium antagonists of different types on cardiovascular stress responses in hypertension., Methods: One-hundred and forty-five patients with mild to moderate hypertension and a mean (+/- s.e.mean) age of 51 +/- 0.9 years received for 8 weeks the phenylalkylamine verapamil sustained release (240 mg) and the dihydropyridine amlodipine (5 mg) in a double-blind cross-over design, both after 4 weeks of placebo. Blood pressure, heart rate and plasma noradrenaline were monitored during 3 min of sustained isometric handgrip and 2 min of cold pressor., Results: Blood pressure was equally reduced by both drugs. After 3 min handgrip, systolic blood pressure, heart rate and rate-pressure product were lower with verapamil compared with amlodipine. Verapamil attenuated the increases in systolic blood pressure (25 +/- 2 vs 30 +/- 2 mmHg, difference 4.6, 95% CI (1.0, 8.1), P < 0.01) and rate-pressure product (3.1 +/- 0.2 vs 3.6 +/- 0.3 x 10(3) mmHg x beats min(-1), difference 0.5, 95% CI (0.1, 0.9), P < 0.01) during handgrip compared with amlodipine. Similar results were observed during cold pressor. Plasma noradrenaline levels were lower with verapamil compared with amlodipine at rest and after both tests, but the increases in plasma noradrenaline were not significantly different., Conclusions: Verapamil is more effective in reducing blood pressure and rate-pressure product responses to stress compared with amlodipine. Although plasma noradrenaline is lower with verapamil at rest and after stress, the increase during stress is not different.
- Published
- 2001
- Full Text
- View/download PDF
45. Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination.
- Author
-
Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, Trimarco B, Fitzgerald D, Hedner T, Duprez D, De Leeuw PW, Sever P, Battegay E, Hitzenberger G, de Luca N, Polónia P, Bénétos A, Chastang C, Ollivier JP, and Safar ME
- Subjects
- Arteries physiopathology, Brachial Artery drug effects, Brachial Artery physiopathology, Carotid Arteries drug effects, Carotid Arteries physiopathology, Double-Blind Method, Drug Therapy, Combination, Humans, Hypertension physiopathology, Antihypertensive Agents administration & dosage, Arteries drug effects, Hypertension drug therapy, Indapamide administration & dosage, Perindopril administration & dosage, Vascular Resistance drug effects
- Abstract
Background: Epidemiological studies have shown that increased arterial stiffness and wave reflections, major determinants of systolic and pulse pressure, are associated with morbidity and mortality. Therapeutic trials based on cardiovascular mortality have recently shown that reduction of systolic blood pressure (SBP) requires normalization of both large-artery stiffness and wave reflections., Aims: To compare the antihypertensive effects of the very-low-dose combination of perindopril (2 mg) and indapamide (0.625 mg) (one or two tablets per day) with the beta-blocking agent atenolol (50 mg; one or two tablets per day) in order to determine whether the combination decreased SBP and pulse pressure more than did atenolol, and whether this decrease occurred in relation to a reduction in arterial stiffness [aortic pulse wave velocity (PWV)] or a decrease in the intensity of, or delay in, wave reflections (augmentation index, measured by applanation tonometry) or a combination of both., Material and Methods: This was a double-blind randomized study in 471 individuals with essential hypertension followed for 12 months. Arterial pressure was measured in the brachial artery (mercury sphygmomanometer) and in the carotid artery (applanation tonometry)., Results: For the same reduction in diastolic blood pressure (DBP), the combination of perindopril and indapamide decreased brachial SBP and pulse pressure significantly more than did atenolol (adjusted differences between groups -6.2 +/- 1.5 and -5.5 +/- 1.0 mmHg, respectively; P < 0.001). This difference was even more pronounced for the carotid than for the brachial artery. Whereas both antihypertensive agents similarly decreased PWV, only the combination significantly attenuated wave reflections., Conclusion: Normalization of SBP, pulse pressure and arterial function--a haemodynamic profile known to improve survival significantly in hypertensive populations at high cardiovascular risk--was achieved to a greater extent with a very-low-dose combination of perindopril and indapamide than with atenolol.
- Published
- 2001
46. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study.
- Author
-
Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti-Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, van Roon AM, and Smit AJ
- Subjects
- Adult, Aged, Amlodipine administration & dosage, Antihypertensive Agents administration & dosage, Autonomic Nervous System physiopathology, Baroreflex drug effects, Blood Pressure drug effects, Calcium Channel Blockers administration & dosage, Carrier Proteins administration & dosage, Cross-Over Studies, Dihydropyridines administration & dosage, Double-Blind Method, Female, Heart Rate drug effects, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Treatment Outcome, Verapamil administration & dosage, Amlodipine pharmacology, Antihypertensive Agents pharmacology, Autonomic Nervous System drug effects, Calcium Channel Blockers pharmacology, Carrier Proteins pharmacology, Dihydropyridines pharmacology, Hypertension drug therapy, Steroid Isomerases, Verapamil pharmacology
- Abstract
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine) and a nondihydropyridine (verapamil) on autonomic function in patients with mild to moderate hypertension. A total of 145 patients with a diastolic blood pressure (BP) between 95 and 110 mm Hg received 8 weeks of verapamil sustained release (240 mg) and amlodipine (5 mg) in a prospective randomized, double blind, cross-over study, both after 4 weeks of placebo. The 24-h autonomic balance was measured by analysis of 24-h heart rate variability and short-term autonomic control of BP by baroreflex sensitivity measurements. Plasma norepinephrine was sampled at rest. Blood pressure was equally reduced from 153/100 mm Hg to 139/91 mm Hg with verapamil and 138/91 mm Hg with amlodipine, P = .50/.59. The low- to high-frequency ratio (LF/HF), reflecting sympathovagal balance, was higher with amlodipine than with verapamil (4.66 v 4.10; P = .001). Baroreflex function was improved by both treatments; however, baroreflex sensitivity (BRS) was significantly higher with verapamil than with amlodipine (8.47 v 8.06 msec/mm Hg; P = .01). Plasma norepinephrine (NE) level was higher with amlodipine than with verapamil (1.59 v 1.32 nmol/L; P < .0001). Amlodipine induces a shift in sympathovagal balance, as measured by heart rate variability indices and plasma NE, toward sympathetic predominance compared with vagal predominance with verapamil. Short-term autonomic control of BP, as assessed by BRS, is more effectively improved by verapamil than by amlodipine. These contrasting effects on autonomic function suggest that the nondihydropyridine calcium antagonist verapamil may have additional beneficial effects beyond lowering BP compared with the dihydropyridine amlodipine.
- Published
- 2001
- Full Text
- View/download PDF
47. Acute effects of haemodialysis on endothelial function and large artery elasticity.
- Author
-
Kosch M, Levers A, Barenbrock M, Matzkies F, Schaefer RM, Kisters K, Rahn KH, and Hausberg M
- Subjects
- Brachial Artery physiopathology, Carotid Arteries physiopathology, Elasticity, Female, Humans, Male, Middle Aged, Regional Blood Flow, Time Factors, Vasodilation, Arteries physiopathology, Endothelium, Vascular physiopathology, Renal Dialysis
- Abstract
Background: Disturbances of functional properties of large arteries contribute to increased cardiovascular morbidity and mortality in patients with end-stage renal disease. However, it is not clear whether haemodialysis per se acutely affects mechanical vessel wall properties or endothelial function., Methods: Twenty-five chronic haemodialysis patients (mean+/-standard error of the mean (SEM): age 52+/-5 years; time on dialysis 63+/-7 months; blood pressure 132+/-4/72+/-2 mmHg) were studied before and immediately after a haemodialysis (HD) session using a polysulphone dialyser (ultrafiltration 1460+/-54 ml), as well as on the following day. Blood pressure was measured with an automatic sphygmomanometer and applanation tonometry. End-diastolic diameter and distension of the brachial and carotid arteries were measured by Doppler frequency analysis of vessel wall movements in M-mode using a multigate pulsed Doppler system and aortic pulse wave velocity (PWV) by an automatic device (Complior). Endothelial function was determined as brachial artery flow-mediated dilation (FMD) and compared with endothelium-independent nitroglycerine-induced dilation (NMD)., Results: FMD was 7.9+/-1.8% in patients before HD and did not change significantly after HD or in the dialysis-free intervall (6.7+/-2.1 and 7.1+/-2.0%, respectively; NS). The same was true for NMD and PWV (12.6+/-0.8 m/s before HD, 12.8+/-0.8 m/s after HD, and 11.9+/-0.7 m/s on the HD-free day). Carotid distensibility coefficients decreased significantly during HD (from 18.1+/-1.9 x 10(-3)/kPa to 16.7+/-2.2 x 10(-3)/kPa, P<0.05) and increased again on the HD-free day (19.8+/-2.4 x 10(-3)/kPa). However, when corrected for blood pressure by tonometry, isobaric carotid distensibility did not change significantly. Brachial artery distensibility also did not show significant acute changes., Conclusions: Haemodialysis per se did not have a significant effect on endothelial function or large artery mechanical vessel wall properties in patients on maintenance dialysis therapy.
- Published
- 2001
- Full Text
- View/download PDF
48. Arterial distensibility and pulse wave velocity in patients with primary hyperparathyroidism before and after parathyroidectomy.
- Author
-
Kosch M, Hausberg M, Barenbrock M, Posadzy-Malaczynska A, Kisters K, and Rahn KH
- Subjects
- Blood Flow Velocity, Blood Pressure, Brachial Artery diagnostic imaging, Brachial Artery pathology, Carotid Artery, Common diagnostic imaging, Carotid Artery, Common pathology, Elasticity, Female, Humans, Hyperparathyroidism blood, Hyperparathyroidism pathology, Hyperparathyroidism surgery, Male, Middle Aged, Parathyroid Hormone blood, Pulsatile Flow, Tunica Intima pathology, Tunica Media pathology, Ultrasonography, Doppler, Pulsed, Brachial Artery physiopathology, Carotid Artery, Common physiopathology, Hyperparathyroidism physiopathology, Parathyroidectomy
- Abstract
Aims: There is evidence that secondary hyperparathyroidism alters arterial vessel wall properties. However, it is unclear whether effects of parathyroid hormone (PTH) on the vascular wall are direct or permissive and related to hypertension and renal failure. To assess early direct effects of PTH on large artery wall properties isobaric distensibility (DC), pulse wave velocity (PWV) and intima-media thickness (IMT) were studied before and after parathyroidectomy (Ptx) in patients with primary hyperparathyroidism (pHPT)., Methods: DC and IMT of the brachial and carotid artery were measured by echo-tracking and tonometry, PWV by the automatic Complior-device at baseline and 6 months after Ptx in 20 patients with pHPT (data mean +/- SEM, age 45+/-5 years, PTH 240+/-61 ng/l). Cardiovascular risk factors like diabetes, hypertension, renal insufficiency and hypercholesterolemia were excluded. Twenty healthy volunteers matched for age, sex and blood pressure served as controls., Results: Six months after Ptx, PTH decreased to normal; however, blood pressure levels and vessel wall parameter remained unchanged. At baseline, there were no significant differences in brachial and carotid IMT (0.48+/-0.04 and 0.62+/-0.04 mm vs. 0.47+/-0.06 and 0.61+/-0.06 mm), radial and aortic PWV (9.1+/-0.4 and 9.9+/-0.7 m/s vs. 9.2+/-0.5 and 10.0+/-0.6 m/s), brachial and isobaric carotid DC (10.1+/-1.4 and 19.5+/-3.4 10(-3)/kPa vs. 9.1+/-0.9 and 20.4+/-3.2 10(-3)/kPa) or artery diameter between patients and controls., Conclusions: Structural and viscoelastic properties of large arteries are not disturbed and not influenced by parathyroidectomy in patients with early pHPT devoid of hypertension and renal disease. We conclude that increased PTH levels per se are not associated with alterations of mechanical arteriall wall properties; permissive factors like renal insufficiency may be necessary to mediate vessel wall alterations in patients with hyperparathyroidism.
- Published
- 2001
49. Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study.
- Author
-
Zanchetti A, Hansson L, Ménard J, Leonetti G, Rahn KH, Warnold I, and Wedel H
- Subjects
- Aged, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Cardiovascular Diseases chemically induced, Cardiovascular Diseases epidemiology, Female, Guidelines as Topic, Humans, Hypertension physiopathology, Incidence, Male, Middle Aged, Risk Assessment, World Health Organization, Antihypertensive Agents adverse effects, Hypertension drug therapy
- Abstract
Background: The Hypertension Optimal Treatment (HOT) Study provided information about cardiovascular events in 18,790 hypertensives, subjected to pronounced blood pressure lowering for a mean of 3.8 years., Methods and Results: The HOT Study data have been further analysed after risk stratification of the patients (1999 World Health Organization and International Society of Hypertension guidelines criteria): (i) no patients of the HOT Study were classified as low risk, 50% were classified as medium risk, 20.2% as high risk and 29.8% as very high risk; (ii) incidence of cardiovascular events in these patients with excellent blood pressure control [92% had diastolic blood pressure (DBP) < or = 90 mmHg] remained proportional to pretreatment risk. The relative risk of very high- versus medium-risk strata was between two and three both when HOT Study patients were considered independently of, or within the DBP target group they had been randomized to; and (iii) event rates in all risk strata were calculated to be much lower (possibly 60% lower) than rates expected from baseline risk calculated approximately by the Framingham equation., Conclusions: The low event rate in HOT Study patients is likely to result from pronounced blood pressure lowering, and is not explained by a lower risk profile than in previous controlled trials of antihypertensive treatment. The persistence of a risk gradient despite intensive blood pressure lowering suggests a combination of blood pressure control with other strategies of risk correction and the need to initiate antihypertensive therapy before complications develop.
- Published
- 2001
- Full Text
- View/download PDF
50. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation.
- Author
-
Hausberg M, Kosch M, Stam F, Heidenreich S, Kisters K, Rahn KH, and Barenbrock M
- Subjects
- Brachial Artery diagnostic imaging, Compliance, Double-Blind Method, Endothelium, Vascular diagnostic imaging, Endothelium, Vascular drug effects, Female, Fluvastatin, Humans, Hypercholesterolemia physiopathology, Male, Middle Aged, Postoperative Period, Prospective Studies, Regional Blood Flow physiology, Ultrasonography, Doppler, Pulsed, Brachial Artery drug effects, Brachial Artery physiopathology, Endothelium, Vascular physiopathology, Fatty Acids, Monounsaturated therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Indoles therapeutic use, Kidney Transplantation, Vasodilation drug effects
- Abstract
Background: Hypercholesterolemia may affect both endothelial function and arterial distensibility (DC). Renal transplant recipients (NTX) exhibit advanced structural and functional alterations of arterial vessel walls. The aim of this double-blind, randomized trial was to evaluate the effects of fluvastatin (FLU) on brachial artery flow-mediated vasodilation (FMD) and DC in hypercholesterolemic NTX., Methods: Eighteen NTX received FLU 40 mg/day and 18 NTX placebo (PLA). Before and after six months of treatment, the brachial artery diameter and DC at rest were measured by a Doppler frequency analysis in the M mode, and then changes in diameter during reactive hyperemia (to assess endothelial-dependent FMD) and after 400 microg sublingual nitroglycerin (to assess endothelium-independent vasodilation-NMD)., Results: FLU, but not PLA, treatment resulted in significant decreases in total (from 288 +/- 10 to 239 +/- 8 mg/dL, P < 0.05) and low-density lipoprotein cholesterol (from 182 +/- 779 to 138 +/- 8 mg/dL, P < 0.05). Blood pressure did not differ between FLU- and PLA-treated patients and was not affected by either treatment. Also, the brachial artery baseline diameter was not different between groups and was not affected by FLU or PLA. Brachial artery flow at rest and during reactive hyperemia as measured by pulsed Doppler did not differ between groups. Brachial artery FMD increased with FLU from 0.23 +/- 0.08 to 0.54 +/- 0.08 mm (P < 0.05), whereas PLA did not alter FMD (0.22 +/- 0.07 vs. 0.14 +/- 0.05 mm at baseline and after six months of PLA treatment, respectively, P = NS). In contrast, NMD did not change significantly with either treatment (0.76 +/- 0.13 vs. 0.83 +/- 0.15 mm at baseline and after 6 months of FLU treatment, respectively, P = NS, and 0.64 +/- 0.09 vs. 0.66 +/- 0.10 mm at baseline and after 6 months of PLA treatment, respectively, P = NS). Also, brachial artery DC was not altered by FLU (6.4 +/- 1.0 vs. 5.8 +/- 0.6 x 10-3/kPa, P = NS) or PLA treatment (5.8 +/- 0.6 vs. 6.8 +/- 0.8 x 10-3/kPa, P = NS)., Conclusions: In hypercholesterolemic NTX, the HMG-CoA reductase inhibitor FLU significantly improves brachial artery FMD as a measure of endothelial function after six months of treatment. In contrast, FLU does not have a beneficial effect on brachial artery DC.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.